Johanna Holldack

Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.

Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.

Kupando GmbH is a German biopharmaceutical company that develops agonists to stimulate innate immunity. The company is based in Schoenefeld, Germany. The company was founded in 2018 by Johanna Holldack, who has been the CEO since 2018.

Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.

Kupando GmbH is a German biopharmaceutical company that develops agonists to stimulate innate immunity. The company is based in Schoenefeld, Germany. The company was founded in 2018 by Johanna Holldack, who has been the CEO since 2018.